Cancer-associated fibroblasts promote hepatocellular carcinoma progression through downregulation of exosomal miR-150-3p. Issue 2 (February 2021)
- Record Type:
- Journal Article
- Title:
- Cancer-associated fibroblasts promote hepatocellular carcinoma progression through downregulation of exosomal miR-150-3p. Issue 2 (February 2021)
- Main Title:
- Cancer-associated fibroblasts promote hepatocellular carcinoma progression through downregulation of exosomal miR-150-3p
- Authors:
- Yugawa, Kyohei
Yoshizumi, Tomoharu
Mano, Yohei
Itoh, Shinji
Harada, Noboru
Ikegami, Toru
Kohashi, Kenichi
Oda, Yoshinao
Mori, Masaki - Abstract:
- Abstract: Purpose: Hepatocellular carcinoma (HCC) is a common and deadly cancer. The prognosis of HCC is poor and is related to tumor progression. The malignant potential of HCC is regulated by the tumor microenvironment (TME). As cancer-associated fibroblasts (CAFs) help regulate tumor progression, understanding how they function in HCC could improve patient outcomes. The aim of this study was to determine whether specific microRNAs (miRNAs) in exosomes derived from CAFs might be involved in HCC progression. Methods: MiRNA microarray assay was used to analyze miRNA profiles of exosomes derived from CAFs and normal fibroblasts (NFs) in HCC. Migration and invasion assays were performed to examine the effects of miR-150-3p on HCC in vitro . In addition, the relationships between prognosis of HCC patients and miR-150-3p expression in HCC tissues and plasma exosomes were retrospectively analyzed. Results: MiR-150-3p was significantly reduced in CAFs-derived exosomes, and inhibited HCC migration and invasiveness. MiR-150-3p was transferred from CAFs transfected miR-150-3p to HCC cells through exosomes, and abrogated HCC migration and invasiveness. Furthermore, low miR-150-3p expression in HCC tissues was a significant risk factor for recurrence in HCC patients. More importantly, survival rate in patients with low miR-150-3p levels in plasma exosomes was significantly poor compared with that in patients with high miR-150-3p levels. Conclusions: Overall, our findings suggest thatAbstract: Purpose: Hepatocellular carcinoma (HCC) is a common and deadly cancer. The prognosis of HCC is poor and is related to tumor progression. The malignant potential of HCC is regulated by the tumor microenvironment (TME). As cancer-associated fibroblasts (CAFs) help regulate tumor progression, understanding how they function in HCC could improve patient outcomes. The aim of this study was to determine whether specific microRNAs (miRNAs) in exosomes derived from CAFs might be involved in HCC progression. Methods: MiRNA microarray assay was used to analyze miRNA profiles of exosomes derived from CAFs and normal fibroblasts (NFs) in HCC. Migration and invasion assays were performed to examine the effects of miR-150-3p on HCC in vitro . In addition, the relationships between prognosis of HCC patients and miR-150-3p expression in HCC tissues and plasma exosomes were retrospectively analyzed. Results: MiR-150-3p was significantly reduced in CAFs-derived exosomes, and inhibited HCC migration and invasiveness. MiR-150-3p was transferred from CAFs transfected miR-150-3p to HCC cells through exosomes, and abrogated HCC migration and invasiveness. Furthermore, low miR-150-3p expression in HCC tissues was a significant risk factor for recurrence in HCC patients. More importantly, survival rate in patients with low miR-150-3p levels in plasma exosomes was significantly poor compared with that in patients with high miR-150-3p levels. Conclusions: Overall, our findings suggest that the loss of antitumoral miR-150-3p in CAFs-derived exosomes greatly promotes HCC progression. Exosomal miR-150-3p is a potential prognostic biomarker, and transferring miR-150-3p-loaded exosomes to HCC cells might become a novel therapeutic option. Highlights: MiR-150-3p is reduced in the exosomes of CAFs derived from HCC specimens. Evaluation of exosomal miR-150-3p could help stratify risk in patients with HCC. Transfer of exosomal miR-150-3p to HCC cells may have therapeutic applications. … (more)
- Is Part Of:
- European journal of surgical oncology. Volume 47:Issue 2(2021)
- Journal:
- European journal of surgical oncology
- Issue:
- Volume 47:Issue 2(2021)
- Issue Display:
- Volume 47, Issue 2 (2021)
- Year:
- 2021
- Volume:
- 47
- Issue:
- 2
- Issue Sort Value:
- 2021-0047-0002-0000
- Page Start:
- 384
- Page End:
- 393
- Publication Date:
- 2021-02
- Subjects:
- Extracellular vesicles -- microRNA -- Stromal cells -- and tumor microenvironment
Oncology -- Periodicals
Cancer -- Surgery -- Periodicals
Medical Oncology -- Periodicals
Neoplasms -- surgery -- Periodicals
Cancer -- Chirurgie -- Périodiques
Cancérologie -- Périodiques
Oncologie
Chirurgie (geneeskunde)
Electronic journals
Electronic journals -- Sciences
Electronic journals -- Medicine
Electronic journals
616.994059005 - Journal URLs:
- http://www.ejso.com/ ↗
http://www.sciencedirect.com/science/journal/07487983 ↗
http://www.clinicalkey.com/dura/browse/journalIssue/07487983 ↗
http://www.clinicalkey.com.au/dura/browse/journalIssue/0720048X ↗
http://firstsearch.oclc.org ↗
http://firstsearch.oclc.org/journal=0748-7983;screen=info;ECOIP ↗
http://www.elsevier.com/journals ↗
http://www.harcourt-international.com/journals ↗
http://www.idealibrary.com/cgi-bin/links/toc/ejso ↗ - DOI:
- 10.1016/j.ejso.2020.08.002 ↗
- Languages:
- English
- ISSNs:
- 0748-7983
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3829.745500
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 22657.xml